Overview

Pharmacokinetic Evaluation of EXPAREL in Adults Undergoing Tonsillectomy

Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the pharmacokinetic (PK) profile of a single dose of EXPAREL (133 mg/10 mL) administered intraoperatively per normal infiltration for prolonged analgesia in 12 adult subjects undergoing tonsillectomy with or without removal of the adenoids.
Phase:
Phase 4
Details
Lead Sponsor:
Pacira Pharmaceuticals, Inc
Treatments:
Bupivacaine